triazoles has been researched along with 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bujak, A; Dymek, B; Dzwonek, K; Grygielewicz, P; Gunerka, P; Lamparska-Przybysz, M; Stanczak, A; Wieczorek, M; Zdzalik, D | 1 |
| Alemà , S; Amoreo, CA; Anastasi, S; Borad, MJ; Buglioni, S; Castellani, L; Cristinziano, G; Egan, JB; Lamberti, D; Leonetti, C; Porru, M; Segatto, O; Shi, CX | 1 |
2 other study(ies) available for triazoles and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
| Article | Year |
|---|---|
Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Isoxazoles; Molecular Targeted Therapy; Oxazoles; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Fibroblast Growth Factor; Resorcinols; Stomach Neoplasms; Transforming Growth Factor beta1; Triazoles | 2016 |
HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Cells, Cultured; Cholangiocarcinoma; Drug Combinations; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Microtubule-Associated Proteins; Phenylurea Compounds; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Triazoles | 2019 |